Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144789 · ClinicalTrials.gov registry record · NA
Personalized Therapeutic Neuromodulation for Anhedonic Depression
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 79
- Enrollment target
NCT05144789: Completed NA study, sponsored by Stanford University.
NCT05144789 is a NA study that has completed, run by Stanford University. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05144789, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 79 participants
- Enrollment target
Study Summary
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
Interventions
- DEVICE Active TBS-DLPFC
- DEVICE Active TBS-DMPFC
- DEVICE Sham TBS-DLPFC or DMPFC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05144789
The ClinicalTrials.gov registry entry for NCT05144789 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Active TBS-DLPFC is the first listed.
NCT05144789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05144789 about?
NCT05144789 is a clinical study titled "Personalized Therapeutic Neuromodulation for Anhedonic Depression". This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
What is the current status of trial NCT05144789?
This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2022-05-31. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT05144789?
The interventions under investigation include: Active TBS-DLPFC (DEVICE), Active TBS-DMPFC (DEVICE), Sham TBS-DLPFC or DMPFC (DEVICE).
Who is sponsoring clinical trial NCT05144789?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.